DJIA 17,164.95 -251.90 -1.45%
NASDAQ 4,635.24 -48.17 -1.03%
S&P 500 1,994.99 -26.26 -1.30%
market minute promo


2.62 -0.15 (-5.42%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

VVUS $2.62 -5.42%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.75
Previous Close $2.77
Daily Range $2.61 - $2.77
52-Week Range $2.56 - $7.72
Market Cap $271.6M
P/E Ratio -3.90
Dividend (Yield) $0.00 (0.0%)
Volume 1,531,555
Average Daily Volume 2,431,295
Current FY EPS -$0.76





VIVUS, Inc. (VVUS) Description

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products. Website:

News & Commentary

Newly Approved Weight Loss Method Works by Tricking Your Brain

What's the best way to lose weight? One company thinks it's simple: don't get hungry.

Gallup Says Obesity Rates Climb Again - Can Anti-Obesity Companies Cash In?

Contrave Scripts Continue Increases For Orexigen

Arena's Belviq Prescriptions Fall: More Publicity Is Needed

Novo Nordisk Receives Positive Opinion In Europe On Obesity Treatment

Benzinga's Top #PreMarket Gainers

Arena Pharmaceuticals to Raise Fund Via Share Issuance - Analyst Blog

The 52-Week Low Club for Thursday

Vivus (VVUS) Weak On High Volume

Forget Pills! Could This Device Put an End to Obesity in America?

We've witnessed three oral anti-obesity meds approved since mid-2012, but this newly approved device could be a game-changer.

See More VVUS News...

VVUS's Top Competitors

VVUS $2.62 (-5.42%)
Current stock: VVUS
PFE $31.25 (-1.82%)
Current stock: PFE
JNJ $100.14 (-2.19%)
Current stock: JNJ
RHHBY $33.78 (-1.75%)
Current stock: RHHBY